Principal Financial Group Inc. Raises Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Principal Financial Group Inc. raised its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 68.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 157,798 shares of the specialty pharmaceutical company's stock after acquiring an additional 64,021 shares during the period. Principal Financial Group Inc. owned approximately 0.72% of ANI Pharmaceuticals worth $10,565,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. Millennium Management LLC raised its holdings in shares of ANI Pharmaceuticals by 89.3% during the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock worth $55,437,000 after acquiring an additional 473,097 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in ANI Pharmaceuticals by 4.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company's stock valued at $37,906,000 after buying an additional 30,420 shares during the period. Deep Track Capital LP raised its holdings in ANI Pharmaceuticals by 28.6% during the 4th quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock valued at $35,879,000 after buying an additional 144,214 shares during the period. William Blair Investment Management LLC raised its holdings in ANI Pharmaceuticals by 2.2% during the 4th quarter. William Blair Investment Management LLC now owns 485,268 shares of the specialty pharmaceutical company's stock valued at $26,826,000 after buying an additional 10,440 shares during the period. Finally, Geode Capital Management LLC raised its holdings in ANI Pharmaceuticals by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 428,999 shares of the specialty pharmaceutical company's stock valued at $23,720,000 after buying an additional 3,774 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Ori Gutwerg sold 881 shares of the stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $60.07, for a total transaction of $52,921.67. Following the transaction, the senior vice president owned 89,897 shares of the company's stock, valued at approximately $5,400,112.79. This represents a 0.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher Mutz sold 4,000 shares of the stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total value of $241,800.00. Following the transaction, the insider directly owned 107,317 shares in the company, valued at $6,487,312.65. The trade was a 3.59% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,681 shares of company stock valued at $345,222. 11.10% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Trading Up 2.2%

ANI Pharmaceuticals stock traded up $1.44 during mid-day trading on Thursday, hitting $68.04. The company's stock had a trading volume of 401,195 shares, compared to its average volume of 319,161. The company has a 50 day moving average of $62.88 and a 200-day moving average of $62.58. The stock has a market cap of $1.47 billion, a PE ratio of -53.57 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.98 and a current ratio of 2.66. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. The company had revenue of $197.12 million for the quarter, compared to the consensus estimate of $179.75 million. During the same quarter in the prior year, the company posted $0.82 EPS. ANI Pharmaceuticals's quarterly revenue was up 43.4% on a year-over-year basis. On average, research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ANIP shares. Truist Financial increased their price target on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a report on Monday, April 21st. HC Wainwright assumed coverage on shares of ANI Pharmaceuticals in a report on Thursday, July 10th. They set a "buy" rating and a $84.00 price target on the stock. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Finally, Guggenheim reiterated a "buy" rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $78.88.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.